Mentari Therapeutics Inc. (MTRI)
NASDAQ: MTRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MTRI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $856.94M
- Dividend yield
- None
- 52-week range
- 5.75 – 23.30
- Day range
- 13.01 – 14.78
- Volume / Avg
- 85.12K / 19.42K
- Beta
- —
- Shares outstanding
- 58.30M
- Next earnings
- Feb 10, 2027
52-week range
MTRI stock today
Shares of Mentari Therapeutics (MTRI) finished lower on Nov 20 at $14.70, a drop of 3.57% or $0.545 per share, versus the S&P 500's 3.70% decline. Volume was 4.4x the average at 85.12K shares, a sign of unusually heavy trading. At this level, MTRI sits in the middle of its 52-week range of $5.75 to $23.30: 36.9% below the high and 155.7% above the low.
Mentari Therapeutics's next earnings report is expected on Feb 10, 2027.
Summary generated from market data by MetaCap's automated system. Methodology
About Mentari Therapeutics
Company profileMentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Gregory J. Divis Jr.
- Headquarters
- Sacramento, CA
- Website
- mentaritx.com
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Feb 10, 2027
- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $-0.36 vs —
MTRI news
All MTRI news- InMed Pharmaceuticals Inc. Files Unaudited Financial Statements of Mentari Therapeutics as of September 30, 2026Nasdaq
- Mentari Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million FinancingGlobeNewswire
Mentari Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs MTRI |
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs MTRI |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs MTRI |
| AKTSAktis Oncology Inc. | 16.15 | -1.52% | $901.14M | vs MTRI |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs MTRI |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs MTRI |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs MTRI |
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs MTRI |
Indexes, lists and sector
Mentari Therapeutics stock FAQ
What is Mentari Therapeutics's stock price today?
MTRI last traded at $14.70 as of Nov 20, 4:00 PM EST, down 3.57% on the day. Prices are delayed at least 15 minutes.
Does Mentari Therapeutics pay a dividend?
No. Mentari Therapeutics does not currently pay a regular cash dividend.
When is Mentari Therapeutics's next earnings date?
Mentari Therapeutics is expected to report earnings on Wednesday, February 10, 2027.
Who is Mentari Therapeutics's CEO?
Mr. Gregory J. Divis Jr. is the chief executive officer of Mentari Therapeutics Inc..
Has MTRI ever split its stock?
Yes. The most recent MTRI stock split was a 1-for-10 split on Nov 5, 2026.
What is the MTRI 52-week high?
The 52-week high for MTRI is $23.30 and the 52-week low is $5.75. The stock is currently 36.9% below its high.